Font Size: a A A

Effects Of Sublingual Immunotherapy For Children With Allergic Asthma On FeNO And Lung Function

Posted on:2021-05-22Degree:MasterType:Thesis
Country:ChinaCandidate:W TangFull Text:PDF
GTID:2404330602488934Subject:Clinical Medicine
Abstract/Summary:PDF Full Text Request
Objective:To explore the effects of sublingual specific immunotherapy on children with allergic asthma at various time periods on FeNO and lung function,to evaluate the efficacy of clinical treatment.Methods:This article is a retrospective study,according to the diagnostic criteria for children's allergic asthma in the "Guidelines for the diagnosis and treatment of allergic asthma in China(first edition,2019)",selected 64 children's allergic asthma with dust mite allergy and were treated at the Respiratory Specialist Clinic of Hunan Children's Hospital((The last case collection time at the time of enrollment is December 2018)),with or without other allergen-positive tests(SPT results greater than or equal to++or serum dust mite-specific IgE levels greater than or equal to 3),this patients whose asthma symptom control level assessments are all at a partial control level,and the severity is mild to moderate,According to different treatment methods,it is divided into ICS +SLIT group and ICS group,31 cases in ICS+SLIT group,33 cases in ICS group,and the determination of exhaled nitric oxide(Fractional Exhaled Nitric Oxide,FeNO)and lung function have been completed,ICS+SLIT group combined with dust mite drops sublingual and routine asthma treatment(salmeterol inhalation powder combined with montelukast sodium chewable tablets oral),ICS group was only given conventional asthma treatment(salmeterol inhalation powder combined with montelukast sodium chewable tablets),observe the changes of asthma symptom control level,FeNO and lung function values after 3,6,and12 months of treatment in the two groups and analyze their significance.Results:(1)After 3 months of treatment,there was no statistically significant difference in the level of asthma symptom control between the two groups(P>0.05).After 6 and 12 months of treatment,the comparison of the asthma symptom control level between the two groups,the ICS+SLIT group improved more significantly than the ICS group.(2)After treatment,the FeNO of the two groups decreased to varying degrees,there is a time effect(P<0.05);there is a statistically significant difference in FeNO between the two groups at different treatment points(P<0.05);After 3 months of treatment,the FeNO of the ICS+SLIT group was 29.26±9.89(ppb),compared to the ICS group FeNO of 29.36±9.33(ppb),There was no statistically significant difference(P>0.05).After 6 months of treatment,The FeNO in the ICS+SLIT group was 21.33±6.68(ppb)was significantly lower than the FeNO of the ICS group which was 27.07±9.34(ppb)(P=0.012).After 12 months of treatment,the FeNO of 15.67±4.93(ppb)in the ICS+SLIT group was significantly lower than the 23.25±7.10(ppb)in the ICS group(P=0.000),and the differences were statistically significant.(3)After treatment,the FEV1% of the two groups increased to varying degrees,there is a time effect(P<0.05);there is a statistically significant difference in FEV1% between the two groups at different treatment points(P<0.05);After 6 months of treatment,the FEV1% 91.58±4.76 in the ICS+SLIT group was significantly higher than the FEV1% 89.09±3.86 in the ICS group(P=0.025).After 12 months of treatment,the FEV1% 96.00±5.44 of the ICS+SLIT group was significantly higher than the FEV1% 93.33±5.02 of the ICS group(P=0.046),and the differences were statistically significant.(4)There is a time effect in two groups(P<0.05);there is no statistically significant difference in FVC between the two groups at different treatment points(P>0.05).(5)After treatment,the PEF% of the two groups increased to varying degrees,there is a time effect(P<0.05);there is a statistically significant difference in PEF% between the two groups at different treatment points(P<0.05);After 6 months of treatment,the PEF% of the ICS+SLIT group was 83.87±3.87,which was significantly higher than the ICS group PEF% of 81.85±3.24(P=0.027).After 12 months of treatment,the PEF% of the ICS+SLIT group was 90.16±4.09,which was significantly higher than the PEF% of the ICS group of 87.45±3.81(P=0.008).The differences were statistically significant.Conclusion:Both conventional treatment of allergic asthma and combined SLIT treatment can effectively improve the clinical symptoms of allergic asthma,but the combined clinical treatment of SLIT treatment is more effective,can significantly reduce FeNO and improve lung function.
Keywords/Search Tags:allergic asthma in children, sublingual immunotherapy, FeNO, lung function
PDF Full Text Request
Related items